Press Releases
Keyword Search
2018 | 2017 | 2016 | 2015 | 2014
DateTitle View 
May 10, 2018Pernix Therapeutics Reports First Quarter 2018 Financial Results
May 1, 2018Pernix Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 10
April 23, 2018Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave® for Weight Loss
March 27, 2018Pernix Therapeutics Announces Return to Market of Zohydro® ER with BeadTek® 20 mg
March 8, 2018Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
February 22, 2018Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8
February 16, 2018Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals
February 6, 2018Pernix Announces Appointment of Lead Independent Director and Key Management Team Promotion
January 29, 2018Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ER
January 5, 2018Pernix Announces Reorganization of Sales Force to Focus on Zohydro® ER with BeadTek™ and Silenor®
November 16, 2017Pernix Therapeutics Announces Election of Two Healthcare Industry Veterans to Board of Directors
November 7, 2017Pernix Therapeutics Reports Third Quarter 2017 Financial Results
November 6, 2017Pernix Therapeutics Announces Sale of Non-Core Product
October 26, 2017Pernix Therapeutics to Report Third Quarter 2017 Financial Results on Tuesday, November 7
October 17, 2017Pernix Therapeutics Announces Planned Departure of Chief Financial Officer
July 27, 2017Pernix Therapeutics Reports Second Quarter 2017 Financial Results and Provides Business Update
July 20, 2017Pernix Commences Refinancing Transactions to Fortify Balance Sheet
July 20, 2017Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results
June 28, 2017Pernix Therapeutics Added to Russell Microcap® Index